购物车里还没有商品。
DLin-MC3-DMA
描述
研究领域
图片与验证
−| 应用说明 |
|---|
关键属性
−| CAS 号 | 1224606-06-7 |
|---|---|
| MW | 641.61 |
| 纯度 | >98% |
| 分子式 | C43H79NO2 |
| SMILES | CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC |
储存与操作
−| 储存 | Pure form: -20°C/3 years,4°C/2 years; In solvent: -20°C/1 month |
|---|---|
| 有效期 | 12 months from date of receipt. |
| 危害信息 | Non-Toxic |
| 免责声明 | For research use only |
别名
−相似产品
−Dlin-MeOH [orb1983102]
99.95% (May vary between batches)
1169768-28-8
528.94
C37H68O
5 mg, 50 mg, 1 ml x 10 mM (in DMSO), 2 mg, 10 mg, 25 mg, 100 mg, 500 mg

质量保证
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our 条款与条件和选购指南.
化合物标识
关键属性
−实验方案信息
按应用筛选
按种属筛选
Ye Zeng 1, Mariona Estapé Senti 2, M Clara I Labonia 3, Panagiota Papadopoulou 1, Maike A D Brans 3, Inge Dokter 3 4, Marcel H Fens 5, Alain van Mil 3 4, Joost P G Sluijter 3 4, Raymond M Schiffelers 2, Pieter Vader 2 3, Alexander Kros 1 Fusogenic Coiled-Coil Peptides Enhance Lipid Nanoparticle-Mediated mRNA Delivery upon Intramyocardial Administration ACS Nano, 17(23), 23466–23477 (2023)
应用
反应性
Gangyin Zhao 1 2, Ye Zeng 3, Wanli Cheng 4, Sofia Karkampouna 4 5, Panagiota Papadopoulou 3, Bochuan Hu 3, Shuya Zang 3, Emma Wezenberg 3, Gabriel Forn-Cuní 1, Bruno Lopes-Bastos 1, Marianna Kruithof-de Julio 5, Alexander Kros 3, B Ewa Snaar-Jagalska 1 Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics ACS Nano, (2025)
Hend Mohamed Abdel-Bar et al. Optimizing Exosome Lipid Hybrid Nanoparticles for Enhanced siRNA Delivery and Improved Therapeutic Anticancer Efficacy In Vivo ACS Nano, 19(50), 42658-42674 (2025)
应用
反应性


